ACE and diabetes mellitus: Goals of this policy include increasing the proportion of people with CKD who are aware that they have decreased kidney function, increasing the proportion of individuals with CKD who receive appropriate medical evaluation including evaluation for microalbuminuria, and increasing the proportion of persons with diabetes and CKD who receive recommended medical treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).